AbbVie’s Pharmacyclics files patent suit against BeiGene over BTK rival Brukinsa

Phar­ma­cyclics is bring­ing its BTK bat­tle to court.

The Ab­b­Vie unit filed suit against BeiGene on Tues­day, al­leg­ing the com­pa­ny’s com­pet­ing blood can­cer drug Brukin­sa in­fringes on a new patent around Im­bru­vi­ca.

The patent in ques­tion, dubbed ‘803, was is­sued on Tues­day, the same day Phar­ma­cyclics filed its com­plaint in Delaware fed­er­al court. It cov­ers meth­ods for us­ing a BTK in­hibitor of cer­tain chem­i­cal struc­ture for chron­ic lym­pho­cyt­ic leukemia and small lym­pho­cyt­ic lym­phoma.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN